The purpose of this research study is to find out whether women with severe preeclampsia
taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in
endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as
the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia
prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg)
or placebo to take daily for up to 3 weeks post-delivery.